The Research Progress of PI3K Inhibitors in the Treatment of Lymphoma——Review
10.19746/j.cnki.issn1009-2137.2025.06.045
- VernacularTitle:PI3K抑制剂在淋巴瘤治疗中的研究进展
- Author:
Wen-Jin QIANG
1
;
De-Li KONG
;
Xing-Bin DAI
Author Information
1. 南京中医药大学第一临床医学院,江苏南京 210023
- Publication Type:Journal Article
- Keywords:
lymphoma;
PI3K inhibitors;
phosphatidylinositol-3-kinase/protein kinase B/mammalian target rapamy-cin signaling pathway;
targeted therapy
- From:
Journal of Experimental Hematology
2025;33(6):1834-1839
- CountryChina
- Language:Chinese
-
Abstract:
There is a complex biological mechanism in the phosphatidylinositol-3-kinase(PI3K)/protein kinase B(PKB/Akt)/mammalian target of rapamycin(mTOR)signaling pathway,which plays a key role in the development and development of lymphoma.In this review,the relevant literature of PI3K inhibitor research in the past five years summarized and analyzed,and found that the research and development,application,efficacy,and adverse reactions of PI3K inhibitors are the current research hotspots,and the positive results of PI3K inhibitors in clinical trials and basic research have strongly demonstrated the potential of PI3K inhibitors in personalized treatment of lymphoma.In order to maximize the clinical benefits,a variety of strategies need to be explored,including novel drugs with better selectivity and safety,and related combination therapies.
